zm 241385 has been researched along with atl 146e in 8 studies
| Studies (zm 241385) | Trials (zm 241385) | Recent Studies (post-2010) (zm 241385) | Studies (atl 146e) | Trials (atl 146e) | Recent Studies (post-2010) (atl 146e) |
|---|---|---|---|---|---|
| 401 | 3 | 124 | 54 | 0 | 6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, ZG; Jacobson, KA | 1 |
| de Lera Ruiz, M; Lim, YH; Zheng, J | 1 |
| Linden, J; Macdonald, TL; Peirce, SM; Rieger, JM; Skalak, TC | 1 |
| Duling, BR; Linden, J; Platts, SH | 1 |
| Day, YJ; Huang, L; Linden, J; Marshall, MA; McDuffie, MJ; Okusa, MD | 1 |
| Lappas, CM; Linden, J; Rieger, JM | 1 |
| Linden, J; Marshall, MA; Murphree, LJ; Sullivan, GW | 1 |
| Ellman, PI; Kern, JA; Kron, IL; Laurent, JJ; Linden, J; Maxey, TS; Okonkwo, DO; Reece, TB; Tache-Leon, C; Tribble, CG | 1 |
2 review(s) available for zm 241385 and atl 146e
| Article | Year |
|---|---|
Adenosine receptors as therapeutic targets.
Topics: Animals; Disease; Drug Therapy; Humans; Ligands; Molecular Structure; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1; Signal Transduction; Structure-Activity Relationship | 2006 |
Adenosine A2A receptor as a drug discovery target.
Topics: Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Crystallography, X-Ray; Drug Discovery; Humans; Ligands; Protein Conformation; Receptor, Adenosine A2A; Signal Transduction | 2014 |
6 other study(ies) available for zm 241385 and atl 146e
| Article | Year |
|---|---|
Selective A(2A) adenosine receptor activation reduces skin pressure ulcer formation and inflammation.
Topics: Animals; Cell Line; Cyclohexanecarboxylic Acids; Dermatitis; Drug Combinations; Humans; Ischemia; Leukocytes; Male; Necrosis; Pressure Ulcer; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1; Reference Values; Regional Blood Flow; Reperfusion Injury; Skin; Triazines; Triazoles | 2001 |
Rapid modification of the glycocalyx caused by ischemia-reperfusion is inhibited by adenosine A2A receptor activation.
Topics: Animals; Arterioles; Biotransformation; Capillaries; Cyclohexanecarboxylic Acids; Erythrocytes; Glycocalyx; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Purines; Receptor, Adenosine A2A; Reperfusion Injury; Triazines; Triazoles | 2003 |
Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of chemokine induction.
Topics: Adenosine A2 Receptor Agonists; Animals; Blood Cells; Chemokines; Cyclohexanecarboxylic Acids; Cytokines; Drug Administration Schedule; Edema; Gene Deletion; Ischemia; Leukocytes; Liver; Liver Circulation; Liver Diseases; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Purines; Radioligand Assay; Receptor, Adenosine A2A; Reperfusion Injury; RNA, Messenger; Triazines; Triazoles | 2004 |
A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Animals; CD4-Positive T-Lymphocytes; Cell Line; Cyclic AMP; Cyclohexanecarboxylic Acids; Gene Dosage; Humans; Interferon-gamma; Lymphocyte Activation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Purines; Receptor, Adenosine A2A; Receptors, Antigen, T-Cell; RNA, Messenger; Rolipram; Triazines; Triazoles | 2005 |
Lipopolysaccharide rapidly modifies adenosine receptor transcripts in murine and human macrophages: role of NF-kappaB in A(2A) adenosine receptor induction.
Topics: Animals; Cells, Cultured; Cyclohexanecarboxylic Acids; Gene Expression Regulation; Humans; Lipopolysaccharides; Macrophages; Mice; NF-kappa B; Nitriles; Protein Binding; Purines; Receptor, Adenosine A2A; RNA, Messenger; Sulfones; Transcription, Genetic; Triazines; Triazoles; Tumor Necrosis Factor-alpha | 2005 |
Functional and cytoarchitectural spinal cord protection by ATL-146e after ischemia/reperfusion is mediated by adenosine receptor agonism.
Topics: Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Animals; Cell Survival; Cyclohexanecarboxylic Acids; Disease Models, Animal; Microtubule-Associated Proteins; Neurons; Neuroprotective Agents; Paraplegia; Purines; Rabbits; Receptor, Adenosine A2A; Reperfusion Injury; Spinal Cord; Spinal Cord Ischemia; Time Factors; Triazines; Triazoles | 2006 |